Mindset Pharma Files Patent for Quickest, Cheapest Method to Synthesize Psilocybin
“Based on our research, we think we’re able to get to psilocybin in fewer steps than any of the other published methods,” says the company’s CEO.
“Based on our research, we think we’re able to get to psilocybin in fewer steps than any of the other published methods,” says the company’s CEO.
Dr. Grace Blest-Hopley tells Psychedelic Spotlight that the compound has anti-inflammatory effects on the brain, and explains how her team will investigate further through psilocybin retreats for veterans.
The subcommittee’s review is the largest of its kind to be conducted in the state, which legalized psilocybin for therapeutic and medicinal purposes last November.
CEO Spencer Hawkswell calls current exemptions for terminally ill under Section 56 of Canada’s Controlled Drugs and Substances Act a “half-assed solution,” and is lobbying for more.
Republican Tracy Pennycuick and Democrat Jennifer O’Mara are the latest politicians to take notice of the proven therapeutic use of psilocybin.
The global supply chain of regulated psilocybin and ibogaine continues to grow as these Canadian companies beef up manufacturing efforts.
A group psilocybin study paves the way for increased scalability of novel treatments that typically require a lot of time for both the patient and therapist.
The OTCQB is a middle-tier market for entrepreneurial and development stage American and international companies.
This week in psychedelic business news: It’s all about partnerships and acquisitions designed to advance psychedelic therapies for depression, suicidal ideation, pain, and more.
Decriminalization is one step behind legalization. Selling entheogenic plants or fungi remains a felony that could warrant prison time.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.